OR WAIT null SECS
March 28, 2022
Xipere is a targeted treatment that is delivered via an injection to the back of the eye to treat macular edema associated with uveitis, a form of eye inflammation.
March 23, 2022
Cystaran is a topical ophthalmic therapy that is used to treat a rare genetic disorder.
March 11, 2022
This expands commercial coverage to 118 million lives and Medicare coverage to 7.1 million lives.
November 01, 2021
Vuity, developed by Allergan, is a once-daily eye drop to treat presbyopia.
October 25, 2021
Xipere is delivered via an injection to the back of the eye to treat macular edema associated with uveitis, a form of eye inflammation.
October 22, 2021
Genentech’s Susvimo is a refillable implant that delivers medication continuously for up to six months.
October 18, 2021
Tyrvaya is a twice daily nasal spray, a first for the treatment of dry eye disease.
September 20, 2021
Biogen/Samsung Bioepis’ Byooviz is a biosimilar of Genentech’s Lucentis.
June 14, 2021
Three commercial plans now cover the corticosteroid Eysuvis.
April 23, 2013
FDA approved a new fixed-dose combination ophthalmic suspension of a carbonic anhydrase inhibitor (brinzolamide 1.0%) and an alpha 2 adrenergic receptor agonist (brimonidine tartrate 0.2%), which is indicated for the reduction of intraocular pressure in patients with primary open-angle glaucoma or ocular hypertension.
